GSK to acquire Nuvalent for US$10.6 billion

Source:Business Times

02 — Who / Subject

GSK

03 — Where / Locus

UK / USA

04 — When / Temporality

June 9, 2026

Verified: June 9, 2026

05 — Why / Core Summary

"GSK agreed to buy biotech firm Nuvalent for US$10.6 billion. The acquisition aims to strengthen GSK's oncology franchise, specifically lung cancer treatments. GSK will pay US$124 per share, a 40% premium over the closing price."

Conflict Analysis

This acquisition represents a major strategic move by GSK to revitalize its oncology pipeline under new leadership.

Recommended Background Resource

Affiliate / AdAI Curation

The Billion Dollar Molecule: One Company's Quest for the Perfect Drug

Author: Barry Werth

This classic book provides deep insight into the high-stakes world of biotech R&D and the intense pressure pharmaceutical companies face to acquire innovative drug candidates to sustain their pipelines, mirroring the strategic logic behind GSK's acquisition of Nuvalent.

Explore Background Book (Amazon)

As an Amazon Associate, COMPAMIR earns from qualifying purchases.

Post